Growth hormone status during long-term hexarelin therapy.

Rahim A, O'Neill PA, Shalet SM

The Journal of clinical endocrinology and metabolism1 May 1998Cited by 22 (Europe PMC)

PMID9589671DOI10.1210/jcem.83.5.4812PepBankPUB-09589671

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults, 16 weeks of twice-daily hexarelin lowered the GH response to a hexarelin injection at week 4 and week 16 compared with baseline.
In plain wordsIn adults, the growth hormone response to a hexarelin injection became smaller after 4 and 16 weeks of hexarelin treatment.
Peptide
Hexarelin
Outcome
DecreaseGH response (AUCGH) to hexarelin during 16 weeks of therapy
Study
n: not reported in source
Comparator
Baseline (week 0)
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
AUCGH
19.1 micrograms/L.h
week 0
AUCGH
13.1 micrograms/L.h
week 1
AUCGH
12.3 micrograms/L.h
week 4
AUCGH
10.5 micrograms/L.h
week 16
AUCGH
19.4 micrograms/L.h
week 20
Source sentences
Summary
The mean (+/- SEM) area under the GH curve (AUCGH) at weeks 0, 1, 4, 16, and 20 were 19.1 +/- 2.4 micrograms/L.h, 13.1 +/- 2.3 micrograms/L.h, 12.3 +/- 2.4 micrograms/L.h, 10.5 +/- 1.8 micrograms/L.h, and 19.4 +/- 3.7 micrograms/L.h, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Further analysis showed that, compared with baseline, the decrease in AUCGH at week 4 and week 16 were significant (P < 0.05 and P < 0.01, respectively).
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967101
02HumanNon-randomized trialEfficacy outcome
In adults, four weeks after hexarelin therapy ended, the GH response to hexarelin increased compared with week 16 and did not differ from week 0.
In plain wordsIn adults, the growth hormone response to hexarelin came back four weeks after treatment stopped, to about the starting level.
Peptide
Hexarelin
Outcome
IncreaseGH response (AUCGH) 4 weeks after stopping hexarelin
Study
n: not reported in source
Comparator
Week 16 on therapy
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Four weeks after completion of hexarelin therapy, the AUCGH increased significantly, compared with AUCGH at week 16 (P < 0.05), and was not significantly different from that at week 0.
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967102
03HumanNon-randomized trialEfficacy outcome
In adults, serum IGF-I did not change significantly during 16 weeks of hexarelin and 4 weeks after.
In plain wordsIn adults, hexarelin treatment did not significantly change blood IGF-I.
Peptide
Hexarelin
Outcome
No significant changeSerum IGF-I over 20 weeks
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
P value
0.24
IGF-I
Source sentences
Summary
Serum IGF-I and IGF binding protein-3 did not change significantly over the 20-week period (P = 0.24 and P = 0.74, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967103
04HumanNon-randomized trialEfficacy outcome
In adults, serum IGF binding protein-3 did not change significantly during 16 weeks of hexarelin and 4 weeks after.
In plain wordsIn adults, hexarelin treatment did not significantly change blood IGF binding protein-3.
Peptide
Hexarelin
Outcome
No significant changeSerum IGF binding protein-3 over 20 weeks
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
P value
0.74
IGF binding protein-3
Source sentences
Summary
Serum IGF-I and IGF binding protein-3 did not change significantly over the 20-week period (P = 0.24 and P = 0.74, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967104
05HumanNon-randomized trialEfficacy outcome
In adults, serum C-terminal propeptide of type I collagen was higher at week 16 of hexarelin than at baseline.
In plain wordsIn adults, one bone formation marker was higher after 16 weeks of hexarelin than at the start.
Peptide
Hexarelin
Outcome
IncreaseSerum C-terminal propeptide of type I collagen at week 16
Study
n: not reported in source
Comparator
Baseline (week 0)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
P value
0.019
week 16 vs baseline
Source sentences
Summary
Of the bone markers measured, only serum C-terminal propeptide of type I collagen changed significantly and was higher at week 16, compared with baseline (P = 0.019).
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967105
06HumanNon-randomized trialEfficacy outcome
In adults, the other measured bone formation and resorption markers did not change significantly during hexarelin therapy.
In plain wordsIn adults, the other bone markers did not change significantly during hexarelin treatment.
Peptide
Hexarelin
Outcome
No significant changeOther bone formation and resorption markers
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Of the bone markers measured, only serum C-terminal propeptide of type I collagen changed significantly and was higher at week 16, compared with baseline (P = 0.019).
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967106
07HumanNon-randomized trialEfficacy outcome
In adults, total body fat did not change significantly at week 16 of hexarelin compared with baseline.
In plain wordsIn adults, body fat did not change significantly after 16 weeks of hexarelin.
Peptide
Hexarelin
Outcome
No significant changeTotal body fat at week 16
Study
n: not reported in source
Comparator
Baseline (week 0)
Outcome group
Body composition · Metabolic and weight
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
P value
0.6
total body fat
Source sentences
Summary
Total body fat, lean body mass, and bone mineral density had not changed significantly at week 16, compared with baseline (P = 0.6, P = 0.3, and P = 0.3, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967107
08HumanNon-randomized trialEfficacy outcome
In adults, lean body mass did not change significantly at week 16 of hexarelin compared with baseline.
In plain wordsIn adults, lean body mass did not change significantly after 16 weeks of hexarelin.
Peptide
Hexarelin
Outcome
No significant changeLean body mass at week 16
Study
n: not reported in source
Comparator
Baseline (week 0)
Outcome group
Body composition · Metabolic and weight
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
P value
0.3
lean body mass
Source sentences
Summary
Total body fat, lean body mass, and bone mineral density had not changed significantly at week 16, compared with baseline (P = 0.6, P = 0.3, and P = 0.3, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967108
09HumanNon-randomized trialEfficacy outcome
In adults, bone mineral density did not change significantly at week 16 of hexarelin compared with baseline.
In plain wordsIn adults, bone mineral density did not change significantly after 16 weeks of hexarelin.
Peptide
Hexarelin
Outcome
No significant changeBone mineral density at week 16
Study
n: not reported in source
Comparator
Baseline (week 0)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.5 micrograms/kg BW twice daily · subcutaneous · 16 weeksAs given in this study (human).
Measurements
P value
0.3
bone mineral density
Source sentences
Summary
Total body fat, lean body mass, and bone mineral density had not changed significantly at week 16, compared with baseline (P = 0.6, P = 0.3, and P = 0.3, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We have, therefore, assessed the effects of 16 weeks of twice-daily s.c. hexarelin therapy (1.5 micrograms/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy.
Report a problemFND-0958967109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.